Cargando…
Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction
The evolution of cancer therapies has led to marked improvement in survival of those affected by childhood malignancies, while also increasing the recognition of early and late toxicities associated with cancer therapies. Cardiotoxicity can include cardiomyopathy/heart failure, coronary artery disea...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534565/ https://www.ncbi.nlm.nih.gov/pubmed/34682138 http://dx.doi.org/10.3390/children8100872 |
_version_ | 1784587583463882752 |
---|---|
author | Tunuguntla, Hari P. Puri, Kriti Denfield, Susan W. |
author_facet | Tunuguntla, Hari P. Puri, Kriti Denfield, Susan W. |
author_sort | Tunuguntla, Hari P. |
collection | PubMed |
description | The evolution of cancer therapies has led to marked improvement in survival of those affected by childhood malignancies, while also increasing the recognition of early and late toxicities associated with cancer therapies. Cardiotoxicity can include cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, arrhythmias, and valvular and vascular dysfunction as a result of exposure to chemotherapy and/or radiation. Anthracyclines remain the most common cause of chemotherapy-induced cardiomyopathy (CCM) with varying clinical presentations including: acute, early onset, and late-onset. Many individuals develop cardiac dysfunction over the long-term, ranging from subclinical cardiac dysfunction to end-stage symptomatic heart failure. The focus of this review is on characterization of symptomatic heart failure in children with cancer therapy-related cardiac dysfunction (CTRCD) primarily due to CCM and utilization of advanced heart failure therapies, including ventricular assist device (VAD) support and heart transplantation, with consideration of unique patient-related factors. |
format | Online Article Text |
id | pubmed-8534565 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85345652021-10-23 Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction Tunuguntla, Hari P. Puri, Kriti Denfield, Susan W. Children (Basel) Review The evolution of cancer therapies has led to marked improvement in survival of those affected by childhood malignancies, while also increasing the recognition of early and late toxicities associated with cancer therapies. Cardiotoxicity can include cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, arrhythmias, and valvular and vascular dysfunction as a result of exposure to chemotherapy and/or radiation. Anthracyclines remain the most common cause of chemotherapy-induced cardiomyopathy (CCM) with varying clinical presentations including: acute, early onset, and late-onset. Many individuals develop cardiac dysfunction over the long-term, ranging from subclinical cardiac dysfunction to end-stage symptomatic heart failure. The focus of this review is on characterization of symptomatic heart failure in children with cancer therapy-related cardiac dysfunction (CTRCD) primarily due to CCM and utilization of advanced heart failure therapies, including ventricular assist device (VAD) support and heart transplantation, with consideration of unique patient-related factors. MDPI 2021-09-30 /pmc/articles/PMC8534565/ /pubmed/34682138 http://dx.doi.org/10.3390/children8100872 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tunuguntla, Hari P. Puri, Kriti Denfield, Susan W. Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction |
title | Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction |
title_full | Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction |
title_fullStr | Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction |
title_full_unstemmed | Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction |
title_short | Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction |
title_sort | management of advanced heart failure in children with cancer therapy-related cardiac dysfunction |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534565/ https://www.ncbi.nlm.nih.gov/pubmed/34682138 http://dx.doi.org/10.3390/children8100872 |
work_keys_str_mv | AT tunuguntlaharip managementofadvancedheartfailureinchildrenwithcancertherapyrelatedcardiacdysfunction AT purikriti managementofadvancedheartfailureinchildrenwithcancertherapyrelatedcardiacdysfunction AT denfieldsusanw managementofadvancedheartfailureinchildrenwithcancertherapyrelatedcardiacdysfunction |